Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
85 hedge funds and large institutions have $565M invested in Dicerna Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 21 closing their positions.
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
45% more capital invested
Capital invested by funds: $391M → $565M (+$174M)
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
18% more funds holding
Funds holding: 72 → 85 (+13)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
100% less call options, than puts
Call options by funds: $4K | Put options by funds: $1.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$29.3M |
| 2 |
BM
Bridger Management
New York
|
+$25.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.11M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$22.7M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$9.56M |
| 3 |
Millennium Management
New York
|
-$4.13M |
| 4 |
First Manhattan
New York
|
-$4.09M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$3.64M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Jane Street
New York
| – | -$136K | -14,262 | Closed |
|
|
CC
102
Caxton Corporation
Princeton,
New Jersey
| – | -$125K | -13,074 | Closed |
|
|
LCM
103
Laurion Capital Management
New York
| – | -$112K | -11,754 | Closed |
|
|
CSS
104
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$102K | -10,665 | Closed |
|
|
SFM
105
Signet Financial Management
Parsippany,
New Jersey
| – | -$8K | -800 | Closed |
|
106
Parallax Volatility Advisers
San Francisco,
California
| – | -$8K | -798 | Closed |
|
DRNA Hedge Fund Activity: Q2 2018 in Review
85 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2018, worth a combined $565M — up 45% from $391M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new DRNA positions and 21 closed out — a net gain of 13 holders — while 22 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $29.3M. The largest seller was EcoR1 Capital, cutting an estimated $22.7M.
- 85 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2018, up from 72 in Q1 2018.
- Funds reported $565M of Dicerna Pharmaceuticals, Inc. stock for Q2 2018, up 45% quarter-over-quarter.
- 34 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2018 and 21 closed out, a net change of +13 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2018 was BlackRock, an estimated $29.3M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2018 was EcoR1 Capital, an estimated $22.7M sold.
Based on aggregated 13F filings for Q2 2018.